| RAY-COQUARD, Isabelle |
| Not yet recruiting | 3 | 132 | Europe | Cytoreductive surgery combined with HIPEC, Chemotherapy and bevacizumab (CT-BEV) | Hospices Civils de Lyon | Ovarian Epithelial Cancer | 11/22 | 11/22 | | |
RAINBO-RED, NCT06712472: Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer |
|
|
| Recruiting | 3 | 554 | Europe | Olaparib (300 mg BID) | Gustave Roussy, Cancer Campus, Grand Paris, AstraZeneca | Endometrial Cancer, P53abn | 06/30 | 12/31 | | |
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
|
|
| Recruiting | 3 | 270 | Europe, Canada, US, RoW | avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex | Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group | Low Grade Serous Ovarian Cancer | 10/28 | 02/31 | | |
| Completed | 2 | 91 | Europe | Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab, Chemotherapy - Bevacizumab | ARCAGY/ GINECO GROUP | Ovarian Cancer Stage IV | 09/20 | 03/24 | | |
| Active, not recruiting | 2 | 58 | Europe | Cabozantinib, Placebo | European Organisation for Research and Treatment of Cancer - EORTC, Gynecologic Oncology Group, NHS Greater Glasgow and Clyde | Uterine Sarcoma | 03/22 | 05/24 | | |
NCT03474094: Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy |
|
|
| Recruiting | 2 | 69 | Europe | Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery, 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab. | Centre Leon Berard, Roche Pharma AG | Sarcoma,Soft Tissue | 08/23 | 08/24 | | |
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure |
|
|
| Completed | 2 | 77 | Europe | Lenvatinib, Placebo, Best supportive care | Centre Leon Berard | Gastro Intestinal Stromal Tumour | 01/24 | 04/24 | | |
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers |
|
|
| Active, not recruiting | 2 | 79 | Europe, Canada, US, RoW | Mirvetuximab soravtansine, MIRV, IMGN853 | AbbVie | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 01/24 | 12/24 | | |
|
|
|
| Active, not recruiting | 2 | 225 | Europe, Canada, US | avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063 | Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | 12/24 | 12/26 | | |
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
|
|
| Recruiting | 2 | 900 | Europe | Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab | Centre Leon Berard, National Cancer Institute, France | Malignant Solid Neoplasms | 01/26 | 10/27 | | |
BFR-ESS, NCT03624244: Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) |
|
|
| Recruiting | 2 | 40 | Europe | Aromatase Inhibitors, ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE | Centre Leon Berard | Low Grade Endometrial Stromal Sarcoma | 01/25 | 01/28 | | |
GIST-TEN, NCT05009927: Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) |
|
|
| Recruiting | 2 | 50 | Europe | Imatinib tablets, Glivec | Centre Leon Berard | Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST) | 01/25 | 01/27 | | |
SURPASS-3, NCT05601752: ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer |
|
|
| Recruiting | 2 | 66 | Europe, Canada, US | Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab | Adaptimmune, GOG Foundation | Ovarian Cancer | 08/26 | 08/26 | | |
| Recruiting | 2 | 27 | Europe | Pembrolizumab 25 MG/ML [Keytruda], MK-3475 | ARCAGY/ GINECO GROUP, Merck Sharp & Dohme LLC | Small Cell Ovarian Carcinoma | 06/26 | 02/30 | | |
ALEPRO, NCT05872204: Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer |
|
|
| Recruiting | 2 | 100 | Europe | Abemaciclib, Verzenios, Letrozole, Femara | Universitaire Ziekenhuizen KU Leuven, Kom Op Tegen Kanker, Eli Lilly and Company, European Network of Gynaecological Oncological Trial Groups (ENGOT) | Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor | 10/26 | 10/26 | | |
COTESARC, NCT04216953: MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma |
|
|
| Active, not recruiting | 1/2 | 320 | Europe | Cobimetinib, GDC-0973, Atezolizumab, RO5541267 | Centre Leon Berard | Sarcoma,Soft Tissue | 02/26 | 02/27 | | |
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation |
|
|
| Recruiting | 1/2 | 230 | Europe, US, RoW | PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79 | PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer | 03/26 | 07/26 | | |
| Active, not recruiting | N/A | 40 | Europe | Nivolumab and Ipilimumab | ARCAGY/ GINECO GROUP, Bristol-Myers Squibb | Cervix Cancer | 08/21 | 08/24 | | |
ETIOSARC, NCT03670927: Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults |
|
|
| Completed | N/A | 2237 | Europe | Environmental, occupational and lifestyle-related exposures | Institut National de la Santé Et de la Recherche Médicale, France | Sarcoma, Environmental Exposure, Occupational Exposure, Life Style | 07/24 | 07/24 | | |
ExPEDAJAC, NCT04711733: Supportive Care Needs of Former Child, AYA Cancer Patients, and of Their Parents: Evaluation During Long-term Follow-up |
|
|
| Recruiting | N/A | 180 | Europe | Interview, Self-report questionnaire, Medical consultation | Centre Leon Berard, University of Paris 5 - Rene Descartes, Institut d'Hématologie et d'Oncologie Pédiatrique | Solid Tumor or Lymphoma | 01/23 | 03/24 | | |
PROFILER, NCT01774409: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer |
|
|
| Recruiting | N/A | 10000 | Europe | Blood and tumor samples | Centre Leon Berard | Neoplasms | 07/25 | 07/26 | | |
RNASARC, NCT03375437: - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. |
|
|
| Active, not recruiting | N/A | 376 | Europe | Blood and tumor samples | Centre Leon Berard, Hoffmann-La Roche | Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer | 12/24 | 12/25 | | |
ABLE02, NCT04354233: A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 244 | Europe | Physical activity intervention with connected devices | Centre Leon Berard, Fondation ARC, Janssen, LP | Metastatic Breast Cancer | 06/24 | 06/25 | | |
